Overview

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to determine response rates (partial and complete responses) to nivolumab of recurrent or progressive IDH mutant (grades 2, 3 or 4) gliomas with prior exposure to alkylating agents.

Phase:

Phase 2

Details

Lead Sponsor:

Columbia University
Fabio Iwamoto, MD

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab